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Abstract
Background: Several studies have shown that inactivated, whole-cell oral cholera vac-
cines (OCVs) confer both direct protection on vaccinees and herd protection on popula-
tions. Because our earlier cluster-randomized effectiveness trial (CRT) in urban
Bangladesh failed to detect OCV herd protection, we reanalysed the trial to assess
whether herd effects were masked in our original analysis.
Methods: A total of 267 270 persons were randomized to 90 approximately equal-sized
clusters. In 60 clusters persons aged 1 year and older were eligible to receive OCV and in
30 clusters persons received no intervention and served as controls. We analysed OCV
protection against severely dehydrating cholera for the entire clusters, as in our original
analysis, and for subclusters consisting of residents of innermost households. We hy-
pothesized that if OCV herd protection was attenuated by cholera transmission into the
clusters from the outside in this densely populated setting, herd protection would be
most evident in the innermost households.
Results: During 2 years of follow-up of all residents of the clusters, total protection (pro-
tection of OCV recipients relative to control residents) was 58% [95% confidence interval
(CI): 43%, 70%; P<0.0001], indirect protection (protection of non-OCV recipients in OCV
clusters relative to control participants) was 16% (95% CI: –20%, 41%; P¼0.35) and overall
OCV protection (protection of all residents in the OCV clusters relative to control resi-
dents) was 46% (95% CI: 30%, 59%; P<0.0001). Analyses of the inner 75% and 50%
households of the clusters showed similar findings. However, total protection was 75%
(95% CI: 50%, 87%, P<0.0001), indirect protection 52% (95% CI: –9%, 79%; P¼0.08) and
overall protection 72% (95% CI: 49%, 84%; P<0.0001) for the innermost 25% households.
VC The Author(s) 2019. Published by Oxford University Press on behalf of the International Epidemiological Association. 1
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Conclusion: Consistent with past studies, substantial OCV herd protective effects were iden-
tified, but were unmasked only by analysing innermost households of the clusters. Caution
is needed in defining clusters for analysis of vaccine herd effects in CRTs of vaccines.
Key words: Cholera, cluster-randomized trial, vaccine effectiveness, fried-egg design
Background
Population-level protection by vaccines, including not only
direct protection of vaccinees but also vaccine herd protec-
tion of both vaccinees and non-vaccinees, is recognized to
be critical to the public health impact and cost-effective-
ness of the inactivated, whole-cell based oral cholera vac-
cines (OCVs).1–5 Two of these vaccines are now available
in the global stockpile of oral cholera vaccines managed by
the International Coordinating Group on Vaccine
Provision (http://www.who.int/csr/disease/icg/qa/en/), con-
sisting of members from the Red Cross, Me´decins sans
Frontie`res, the World Health Organization and UNICEF.
In 2011 we initiated a large-scale, cluster-randomized ef-
fectiveness trial (CRT) of the OCV ShancholTM (Shanta
Biotechnics-Sanofi, Hyderabad, India) in a poor urban
slum population in Dhaka, Bangladesh, where cholera is
hyperendemic. A CRT design was selected in order to eval-
uate the population-level, herd protective effects of this
vaccine, since the CRT design offers a powerful approach
to assessing these protective effects in an unbiased fash-
ion.5,6 In contrast to a past CRT of the same OCV,7,8 how-
ever, our CRT revealed lower than expected levels of total
vaccine protection (direct protection of vaccinees plus ad-
ditional protection of vaccinees by vaccine herd effects),
perhaps due to limited vaccine herd protection. Absent
vaccine herd protection was later confirmed in additional
unpublished analyses of the trial, a result that contrasted
with several past studies of herd protection by OCVs.1–3
We wondered whether these surprising findings were
real, perhaps related to the very high level of transmission
of cholera in this densely populated, poor urban setting, or
could possibly have been an artifact of the design of the
study, especially the demarcation of clusters in dense urban
slums in which considerable transmission of cholera to per-
sons inside the clusters may have originated from the out-
side. Such transmission would be predicted to attenuate
the level of measured vaccine herd protection.9,10 To ad-
dress this possibility, we reanalysed OCV protection
against the primary outcome of the trial, severely dehydrat-
ing cholera, using an analytic strategy that has been called
the ‘fried-egg’ approach.11 With this approach, the analysis
is confined to persons residing in the central ‘yolk’ of the
cluster rather than the entire cluster, with the assumption
that the persons residing in the central yolk are protected
against cholera originating outside of the cluster, due to a
buffering effect of persons residing in the outer ‘white’
of the cluster, who act as a barrier to such transmission.
We hypothesized that as the ‘yolk’ of the cluster is
Key Messages
• In our earlier analysis of a cluster-randomized trial (CRT), we observed moderate total vaccine protection (protection
of vaccinees owing both to direct vaccine protection and reduced transmission due to vaccination of the surrounding
population) against severely dehydrating cholera.
• We wondered whether our conventional analysis of the CRT, in which participants in entire clusters were evaluated,
had obscured actual oral cholera vaccine (OCV) herd protection due to transmission of cholera into clusters from the
outside in this dense urban setting.
• We reanalysed the data using an approach called ‘fried-egg analysis’, in which only the innermost residents (‘yolks’)
of the clusters were evaluated for total protection, indirect protection and overall protection by OCV against severely
dehydrating cholera during 2 years of follow-up.
• Programmatically, the findings for the innermost clusters confirm the results of earlier studies indicating the OCVs
confer herd protection, and extend these findings by showing that OCV can confer herd protection also in densely
populated, poor urban settings with endemic cholera.
• Methodologically, the results caution that spuriously negative findings for vaccine herd protection can occur in CRTs
of vaccines in which clusters are not insulated from transmission from the outside, and argue for care in the selection
and analysis of clusters in these studies.
2 International Journal of Epidemiology, 2019, Vol. 0, No. 0
D
ow
nloaded from
 https://academ
ic.oup.com
/ije/advance-article-abstract/doi/10.1093/ije/dyz060/5435914 by guest on 16 April 2019
progressively constricted to central populations residing
further and further from the outer perimeter of the clusters,
vaccine herd protective effects should become more appar-
ent. Herein, we report the findings of this reanalysis.
Methods
The study area and population
We reanalysed the data of CRT of the effectiveness of the
OCV that was conducted in an urban slum area of Dhaka,
Bangladesh.8 This trial was designed to evaluate the popu-
lation-level protective effects of this vaccine when adminis-
tered under programmatic conditions and to assess
whether a behavioural intervention to improve drinking-
water quality and handwashing (WASH) practices added
to the protection conferred by the OCV. Before vaccina-
tion, a census was carried out to register the study area
population. Information was collected using personal digi-
tal assistants (PDAs) from households after verbal consent
of the respondents. A unique identification number was
given to each registered individual and relevant socio-eco-
nomic, demographic and healthcare information was col-
lected. In this CRT residents of 90 geographic clusters in
urban Dhaka were randomized to one of three arms: OCV
alone, OCV combined with the WASH behavioural change
intervention, or no intervention. There was a buffer zone
of at least 30 meters between clusters to minimize the spill-
over of the effect of behavioural intervention. The 90 clus-
ters, with a total population of 267 270, were randomly
assigned to the different arms of the study in blocks of
three, after stratifying the clusters by distance of the cluster
centroid to the nearest study hospital (lower than the me-
dian distance vs the median distance or higher), yielding 30
clusters in each arm with similar numbers of residents in
each of the three trial arms. The average cluster population
size was 2988 (range 2288–4299). For the purpose of this
analysis, we combined the two intervention arms into one
arm of 60 clusters, as the WASH intervention was found to
add little protection against cholera to the OCV and we
wished to increase the statistical power of our analysis.8
Eligibility and interventions
Zero time was defined as the date of the first dose for
vaccinees; median date of the first dose in the cluster for
non-vaccinees in the intervention clusters, and for residents
of the non-intervention clusters, it was the median date of
the first dose among residents of the nearest intervention
cluster. Consenting, non-pregnant residents of clusters of
the two intervention arms were eligible to receive the OCV
if they were 1 year of age or older at zero time. The
behavioural change WASH intervention, which is de-
scribed in detail elsewhere, was targeted to all households
in the clusters of the arm receiving both OCV and WASH.8
OCV was given as a two dose regimen delivered at fixed
vaccination sites, with an interdose interval of at least
14 days. Vaccination was conducted between 17 February
and 16 April, 2011.
Diarrhoea surveillance and definitions
Surveillance for diarrhoea was conducted at all 12 hospi-
tals known to provide care for diarrhoea to the study pop-
ulation. Patients from the study area were identified by use
of household identification cards and/or an on-site com-
puterized database. Clinical data were recorded onto struc-
tured forms after obtaining written informed consent from
the patient or the guardian of the patient in case of a mi-
nor. A fecal specimen was taken from every diarrhoea pa-
tient and transported to the icddr,b (International Centre
For Diarrhoeal Disease Research, Bangadesh) laboratory
for carrying out microbiological tests for Vibrio cholerae
O1 and O139, and enterotoxigenic Escherichia coli, as de-
scribed elsewhere.12–15 A diarrhoeal visit was defined as
having 3 or more loose motions in the 24 hours before pre-
sentation or 1–2 or an indeterminate number of loose
stools with evidence of dehydration according to WHO
criteria.16 Diarrhoeal visits for which the date of onset was
"7 days from the date of discharge for the previous visit
were grouped into the same diarrhoeal episode. The onset
of a diarrhoeal episode was the day of onset of symptoms
reported in the first diarrhoeal visit of the episode. A se-
verely dehydrating cholera case was defined as a diarrhoeal
episode in which severe dehydration by WHO criteria was
noted in at least one constituent visit, there was no passage
of bloody stools in any constituent visit, a fecal specimen
yielded V. cholerae O1 or O139 in at least one constituent
visit, and a domiciliary check confirmed that the patient
had indeed visited the treatment centre for care of diar-
rhoea on the recorded dates of visits for the episode. An
Enterotoxigenic Escherichia coli (ETEC) diarrhoeal epi-
sode was defined as a non-bloody diarrhoeal episode in
which a faecal specimen yielded ETEC, but specimens in
all component visits did not yield V. cholerae O1 or O139.
Defining the yolk for the fried-egg analytic
approach
We used the ‘fried-egg’ approach to reanalyse the data for
this trial.11 We analysed OCV protection for the entire
clusters, as well as for residents of the innermost 75%, in-
nermost 50% or innermost 25% households (‘yolks’) of
the clusters. We hypothesized that if herd protection was
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attenuated by transmission of cholera into the clusters
from the outside, this protection would be most evident in
the innermost households. To demarcate these different
sized ‘yolks’, we calculated the linear distance to the near-
est cluster perimeter for every household and sorted the
households in each cluster in ascending (furthest to closest
to the nearest perimeter) order by distance. We then assem-
bled successive proportions of households, beginning with
the household furthest from the perimeter and proceeding
to include households progressively closer to the nearest
perimeter, until the desired fraction of households was
reached. Before undertaking the analysis, we specified four
fractions of households for analysis: 25% (innermost
yolk), 50%, 75% and 100% (outermost yolk including the
entire cluster), referred to, respectively as P25, P50, P75
and P100. Figure 1 shows the selected households for the
P25 group.
Analysis
As in our original analysis of this trial, severely dehydrat-
ing cholera was the primary outcome of interest.8 We ana-
lysed all measures of OCV protection against severely
dehydrating cholera as the proportionate reduction of dis-
ease incidence [(1-hazard ratio of severely dehydrating
cholera in the intervention clusters vs the control clusters)
x 100%]. For assessment of total OCV protection we com-
pared vaccinees in the intervention clusters vs residents
aged 1 year and older at zero time of the control clusters;
for indirect OCV protection we compared all non-
vaccinees in the intervention clusters vs all residents of the
control clusters; and for overall OCV protection we com-
pared all residents of the intervention clusters vs all resi-
dents of the control clusters.6 For overall and indirect
protection, we analysed all age groups, including those too
young to have been vaccinated. For total protection, we
analysed only persons who would have been age-eligible
for vaccination. We hypothesized that population-level
OCV protection should become more pronounced the lon-
ger the distance of the household from the nearest perime-
ter. As in our earlier analysis,8 we considered all persons
present at the time of the second dose, defined as the date
of the second dose for vaccinees; the median date of the
second dose for one-dose or non-vaccinees in the interven-
tion clusters; and for the non-intervention clusters, the
median date of the second dose among residents of the
nearest intervention cluster. We analysed initial severely
dehydrating cholera episodes occurring from 14days to 2
years after the second dose. Similarly, we analysed initial
ETEC episodes occurring from 14days to 2 years after the
Figure 1. Distribution of study area households (entire study area in the left panel, close-up view of some of the clusters in the right panel) for analy-
ses of the P25 clusters.
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second dose in a bias indicator analysis. This bias indicator
analysis was undertaken because our strategy of analysing
all controls, but only vaccinees and non-vaccinees in the in-
tervention clusters for measurement of total and indirect
protection, respectively, entailed non-randomized compar-
isons. We measured overall, total and indirect protection
by the OCV against severely dehydrating cholera, redefin-
ing the clusters according to the P25, P50, P75 and P100
populations created with the fried-egg design.
We conducted survival analyses, censoring individuals
who died or migrated out before the end of the follow-up
period. In-migrants and infants born after zero time were
not included in the analysis. Because there was little move-
ment between the clusters, there was very little contamina-
tion of the control clusters with migrating vaccinees. We
fitted Cox proportional hazards regression models after
adjusting for age at zero time, sex, and the stratification
variable (distance to the hospital) used for cluster randomi-
zation, as well as variables found to be unequally distrib-
uted at P < 0 .05 in bivariate, baseline comparisons of the
arms of the study for each concentric zone and each type
of population-level OCV protection. We ascertained that
the proportional hazards assumption was fulfilled for each
fitted independent variable in the models. We used robust
sandwich variance estimates to account for the design ef-
fect of cluster randomization, allowing inferences about
vaccine protection at the individual level, and we estimated
the hazard ratios by exponentiation of the coefficient for
the treatment arm variable in these models.17 The 95%
confidence intervals (95% CIs) and P-values were calcu-
lated two-tailed, considering P < 0.05 as the threshold of
statistical significance. All statistical analyses were per-
formed using SAS version 9.4.
Ethical considerations
The study protocol was approved by the Research Review
Committee and the Ethical Review Committee of the
icddr, b, Dhaka, Bangladesh and the Institutional Review
Board of the International Vaccine Institute. Written in-
formed consent was obtained from residents 18 years and
older and from the parents or guardians of residents aged
1–17 years of age during vaccination. Additional assent
was obtained from residents aged 11–17 years. The study
protocol was registered at ClinicalTrials.gov number,
NCT01339845.
Role of the funding source
The study was funded by the Bill and Melinda Gates
Foundation (OPP1171432). The funder had no role in data
analysis, data interpretation or writing of this manuscript.
The corresponding author had full access to all the data in
the study and had final responsibility for the decision to
submit the manuscript for publication.
Results
The assembly of subjects and outcomes for analysis has
been published previously.8 The intervention and non-
intervention groups under analysis for the analysis of over-
all, total and indirect OCV protection were comparable
with respect to distributions of sociodemographic charac-
teristics at zero time except for a few variables (Tables 1–4
and Supplementary Tables S1–S8, available as
Supplementary data at IJE online). For analysis of overall
OCV protection against severely dehydrating cholera,
there were 267 270 individuals and 226 cholera episodes
in the P100 group (Table 5); 205 313 persons and 175
cholera episodes in the P75 group; 136 068 persons and
117 episodes in the P50 group, and 66 473 persons and 49
cholera episodes in the P25 group. Correspondingly, over-
all protection was 46% (95% CI: 30–59%; P-value
<0.0001) for the P100 group, with similar values for the
P75 and P50 groups, but 72% (95% CI: 49–84%; P-value
<0.0001) for the P25 group (Table 5).
Similarly, analysis of total OCV protection in the P100
group yielded an estimate of 58% (95% CI: 43–70%; P-
value <0.0001) (Table 5), with similar estimates for the
P75 and P50 groups, but rose to 75% (95% CI: 50–87%;
P-value <0.0001) when the analysed clusters were re-
stricted to the P25 group. Likewise, indirect OCV protec-
tion was estimated at 16% (95% CI: –20–41%; P-value
¼0.35) in the P100 group, but rose to 52% (95% CI: –9–
79%; P-value ¼0.08) in the P25 group (Table 5).
Finally, we reasoned that the results of our analyses
would be strengthened if we failed to find a similar pattern
of OCV protection for a clinically similar outcome that
OCV was not anticipated to prevent, ETEC diarrhoea. The
analyses showed no overall, total or indirect OCV protec-
tion against ETEC diarrhoea in the P100 group as well as
in the P75, P50 and P25 groups (Table 6).
Discussion
Our reanalysis of this CRT suggests that the analysis of en-
tire clusters for the trial, as we previously reported,8 gave a
false impression that population-level vaccine herd effects
were insignificant when the OCV was given in this dense
urban setting. Indeed, restriction of the analyses to the cen-
tral 25% of the clusters revealed substantial levels of over-
all, total and indirect vaccine protection against severely
dehydrating cholera, although the estimate of indirect pro-
tection was unstable, reflected by a wide sample CI. To
International Journal of Epidemiology, 2019, Vol. 0, No. 0 5
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our knowledge, this is the first study to demonstrate the
impact of using the fried-egg analytic approach on levels of
population-level vaccine protection against an infectious
disease studied in a CRT.
Before discussing the implications of this analysis, it is
important to address several potential limitations. Because
of the design of the fried-egg analysis, our results refer to
OCV herd protection of a population that is also sur-
rounded by a vaccinated population. In this situation, herd
protection could have been conferred not only by vaccina-
tion of the central ‘yolk’ under analysis, but also by the
surrounding vaccinated population. However, we do not
Table 1. Sociodemographic characteristics of the individuals in the vaccine and non-vaccine arms of the study in analysis of the
P100 clusters for total vaccine protection
Variables Intervention
arm (n¼123, 659)
Non-intervention arm
(n¼78, 518)
P valuea
Age at zero time – yearsb 23.22615.75 24.58615.77 <.0001
Male sex - no. (%) 56 196 (45.44) 38 485 (49.01) <.0001
Living in own house - no. (%) 28 011 (22.65) 19 714 (25.11) 0.72
Living in the study area less than 1 year - no. (%) 51 903 (41.97) 31 725 (40.40) 0.67
Living in householdf sharing kitchen with others - no. (%) 108 766 (87.96) 65 258 (83.11) 0.32
Living in household with improved water source - no. (%)c 6 807 (5.50) 4 127 (5.26) 0.73
Living in household using treated water for drinking - no. (%)d 68 138 (55.10) 41 457 (52.80) 0.68
Living in household using fixed place for waste disposal- no. (%) 101 172 (81.82) 60 744 (77.36) 0.36
Living in household having concrete roof - no. (%) 16 194 (13.10) 12 269 (15.63) 0.36
Living in house with sanitary toilet - no. (%) 723 (0.58) 343 (0.44) 0.56
Monthly expenditure of household - Bangladesh takae 10 02764637 979064562 0.31
aThe P values were derived by comparing the differences between the two groups adjusted for cluster effects using generalized estimating equations with the
logit link function for dichotomous variables and the identity link function for dimensional variables.
bZero time was defined as the date of dose 1 for vaccinees, and at the median date of dose 1 of the cycle of vaccination in the clusters for non-vaccinees.
cAn improved water source was defined as own tap.
dWater that was boiled, filtered, or chlorinated was considered to have been treated.
eOne US dollar equals approximately 80 Bangladeshi taka.
fA household was defined as residents living in a compound and sharing the same cooking pot.
Note: 6 values are means6SD.
Table 2. Sociodemographic characteristics of the individuals in the vaccine and non-vaccine arms of the study in analysis of the
P25 clusters for total vaccine protection
Variables Intervention arm
(n¼30 342)
Non-intervention arm
(n¼20 343)
P valuea
Age at zero time - yearsb 23615.81 25615.77 <.0001
Male sex - no. (%) 13 789 (45.45) 9989 (49.10) <.0001
Living in own house - no. (%) 7356 (24.24) 4885 (24.01) 0.98
Living in the study area less than 1 year - no. (%) 12 254 (40.39) 8648 (42.51) 0.74
Living in householdf sharing kitchen with others - no. (%) 26 595 (87.65) 17 256 (84.83) 0.49
Living in household with improved water source - no. (%)c 1511 (4.98) 944 (4.64) 0.76
Living in household using treated water for drinking - no. (%)d 16 963 (55.91) 10 333 (50.79) 0.41
Living in household using fixed place for waste disposal - no. (%) 25 226 (83.14) 15 563 (76.50) 0.34
Living in household having concrete roof - no. (%) 4283 (14.12) 2929 (14.40) 0.74
Living in house with sanitary toilet - no. (%) 180 (0.59) 68 (0.33) 0.33
Monthly expenditure of household - Bangladesh takae 10 10964709 968064048 0.11
aThe P values were derived by comparing the differences between the two groups adjusted for cluster effects using generalized estimating equation with the logit
link function for dichotomous variables and the identity link function for dimensional variables.
bZero time was defined as the date of dose 1 for vaccinees, and at the median date of dose 1 of the cycle of vaccination in the clusters for non-vaccinees.
cAn improved water source was defined as own tap.
dWater that was boiled, filtered, or chlorinated was considered to have been treated.
eOne US dollar equals approximately 80 Bangladeshi taka.
fA household was defined as residents living in a compound and sharing the same cooking pot.
Note: 6 values are means6SD.
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consider this a significant limitation of our analysis, since
this observation does not detract from the validity of the
conclusion that OCV herd protection was observed in this
densely populated, urban setting. Moreover, since OCV is
usually delivered in mass immunization programmes cov-
ering a wide population, a significant fraction of targeted
populations is typically surrounded by a rim of vaccinated
population in such settings. It might also be argued that be-
cause the control clusters in the trial did not receive a com-
parator agent, the estimates of total and indirect OCV
protection might have been biased, since the risk of cholera
might differ between participants and non-participants.
Table 3. Sociodemographic characteristics of the individuals in the vaccine and non-vaccine arms of the study in analysis of the
P100 clusters for indirect vaccine protection
Variables Intervention arm
(n¼45 784)
Non-intervention arm
(n¼80 056)
P valuea
Age at zero time - yearsb 25.11þ15.83 24.10þ15.98 <.0001
Male sex - no. (%) 25 182 (55.00) 39 264 (49.05) <.0001
Living in own house - no. (%) 8222 (17.96) 20 075 (25.08) 0.26
Living in the study area less than 1 year - no. (%) 23 776 (51.93) 32 424 (40.50) 0.0003
Living in householdf sharing kitchen with others - no. (%) 40 813 (89.14) 66 536 (83.11) 0.27
Living in household with improved water source - no. (%)c 2105 (4.60) 4197 (5.24) 0.78
Living in household using treated water for drinking - no. (%)d 25 012 (54.63) 42 276 (52.81) 0.85
Living in household using fixed place for waste disposal- no. (%) 38 141 (83.31) 61 943 (77.37) 0.26
Living in household having concrete roof - no. (%) 7390 (16.14) 12 524 (15.64) 0.98
Living in house with sanitary toilet - no. (%) 286 (0.62) 352 (0.44) 0.53
Monthly expenditure of household - Bangladesh takae 9 923þ4, 962 9 773þ4, 548 0.73
aThe P values were derived by comparing the differences between the two groups adjusted for cluster effects using generalized estimating equation with the logit
link function for dichotomous variables and the identity link function for dimensional variables.
bZero time was defined as the date of dose 1 for vaccinees, and at the median date of dose 1 of the cycle of vaccination in the clusters for non-vaccinees.
cAn improved water source was defined as own tap.
dWater that was boiled, filtered, or chlorinated was considered to have been treated.
eOne US dollar equals approximately 80 Bangladeshi taka.
fA household was defined as residents living in a compound and sharing the same cooking pot.
Note: 6 values are means6SD.
Table 4. Sociodemographic characteristics of the individuals in the vaccine and non-vaccine arms of the study in analysis of the
P25 clusters for indirect vaccine protection
Variables Intervention arm
(n¼11 192)
Non-intervention arm
(n¼20 725)
P valuea
Age at zero time – yearsb 25.07615.70 24.15615.97 <.0001
Male sex - no. (%) 6102 (54.52) 10 176 (49.10) <.0001
Living in own house - no. (%) 2012 (17.98) 4962 (23.94) 0.40
Living in the study area less than 1 year - no. (%) 5708 (51.00) 8843 (42.67) 0.02
Living in householdf sharing kitchen with others - no. (%) 9990 (89.26) 17 588 (84.86) 0.41
Living in household with improved water source - no. (%)c 471 (4.21) 960 (4.63) 0.74
Living in household using treated water for drinking - no. (%)d 6291 (56.21) 10 537 (50.84) 0.59
Living in household using fixed place for waste disposal- no. (%) 9523 (85.09) 15 852 (76.49) 0.25
Living in household having concrete roof - no. (%) 1973 (17.63) 2994 (14.45) 0.72
Living in house with sanitary toilet - no. (%) 70 (0.63) 70 (0.34) 0.20
Monthly expenditure of household – Bangladesh takae 10 05365054 966064034 0.37
aThe P values were derived by comparing the differences between the two groups adjusted for cluster effects using generalized estimating equation with the logit
link function for dichotomous variables and the identity link function for dimensional variables.
bZero time was defined as the date of dose 1 for vaccinees, and at the median date of dose 1 of the cycle of vaccination in the clusters for non-vaccinees.
cAn improved water source was defined as own tap.
dWater that was boiled, filtered, or chlorinated was considered to have been treated.
eOne US dollar equals approximately 80 Bangladeshi taka.
fA household was defined as residents living in a compound and sharing the same cooking pot.
Note: 6 values are means6SD.
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Table 5. Overall, total and indirect OCV protection against severely dehydrating cholera in the differently defined clusters
Measures of protection Intervention arm
(no. of clusters¼60)
Non-intervention arm
(no. of clusters¼30)
Protective effectiveness (PE)a
No. of
persons
No. of
cases
Rate/1000
person-years
No. of
persons
No. of
cases
Rate/1000
person-years
PE (%) 95% CI P value
P100 clusters
Overall 187 214 120 0.53 80 056 106 0.98 46 30 to 59 <0.0001
Total 123 659 64 0.41 78 518 105 0.99 58 43 to 70 <0.0001
Indirect 45 784 43 0.83 80 056 106 0.98 16 $20 to 41 0.3502
P75 clusters
Overall 143 915 97 0.56 61 398 78 0.95 41 21 to 56 0.0005
Total 95 254 56 0.46 60 196 77 0.95 51 30 to 65 <0.0001
Indirectb 35 039 32 0.81 61 398 78 0.95 12 $31 to 43 0.5000
P50 clusters
Overall 95 310 62 0.54 40 758 55 1.00 47 23 to 63 0.0007
Total 63 185 31 0.38 39 960 55 1.02 62 40 to 75 <0.0001
Indirectb 23 156 25 0.95 40 758 55 1.00 1 $60 to 39 0.9557
P25 clusters
Overall 45 748 18 0.32 20 725 31 1.13 72 49 to 84 <0.0001
Total 30 342 11 0.28 20 343 31 1.16 75 50 to 87 <0.0001
Indirect 11 192 7 0.56 20 725 31 1.13 52 $9 to 79 0.0783
Note: for overall and indirect protection, we analysed all age groups, including those too young to have been vaccinated. For total protection, we analysed only
persons who would have been age-eligible for vaccination.
aAdjusted for age at zero time (described in the text), sex, stratification variable (distance to the hospital) for cluster randomization, and the variables found to
be significantly different (P < 0.05) between the arms at baseline.
bIn addition to age, sex and distance to the hospital, the variable ‘living in the study area <1 year’ was adjusted for in analyses of indirect vaccine protection of
the P75 clusters. Because of the small number of outcome events for the P25 group, this variable was not adjusted for in analysis of indirect vaccine protection in
this group.
Table 6. Overall, total and indirect protection against ETEC diarrhoea in the differently defined clusters
Measures of protection Intervention arm
(no. of clusters¼60)
Non-intervention arm
(no. of clusters¼30)
Protective effectiveness (PE)a
No. of
persons
No. of
cases
Rate/1000
person-years
No. of
persons
No. of
cases
Rate/1000
person-years
PE (%) 95% CI P value
P100 clusters
Overall 187 214 277 1.23 80 056 140 1.30 6 –16 to 23 0.5819
Total 123 659 153 0.98 78 518 110 1.04 5 –21 to 26 0.6738
Indirect 45 784 106 2.05 80 056 140 1.30 –65 –113 to –28 <0.0001
P75 clusters
Overall 143 915 213 1.22 61 398 103 1.25 2 –24 to 23 0.8532
Total 95 254 120 0.99 60 196 81 1.00 1 –33 to 24 0.9690
Indirectb 35 039 81 2.05 61 398 103 1.25 –70 –127 to –26 0.0004
P50 clusters
Overall 95 310 153 1.32 40 758 69 1.26 –5 –40 to 21 0.7309
Total 63 185 82 1.02 39 960 55 1.02 0 –42 to 28 0.9574
Indirectb 23 156 61 2.33 40 758 69 1.26 –89 –168 to –34 0.0003
P25 clusters
Overall 45 748 69 1.24 20 725 36 1.32 6 –41 to 37 0.7651
Total 30 342 38 0.98 20 343 32 1.19 13 –33 to 48 0.4320
Indirectb 11 192 25 1.99 20 725 36 1.32 –55 –158 to 7 0.0953
Note: for overall and indirect protection, we analysed all age groups, including those too young to have been vaccinated. For total protection, we analysed only
persons who would have been age-eligible for vaccination.
aAdjusted for age at zero time (described in the text), sex, stratification variable (distance to the hospital) for cluster randomization, and the variables found to
be significantly different (P < 0.05) between the arms at baseline.
bIn addition to age, sex, and distance to the hospital, the variable ‘living in the study area less than <1 year’ was adjusted for in analyses of indirect vaccine
protection.
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Arguing against this possibility, however, is the observa-
tion that our analysis of a bias indicator condition, ETEC
diarrhoea, against which OCV should have had no protec-
tive effect, gave no evidence of either of these types of herd
protection. Indeed, our analyses found that the rate of
ETEC diarrhoea was higher in the unvaccinated subgroup
in the intervention clusters than that in all residents in the
control clusters, suggesting a possible selection bias that
would make our findings for OCV indirect protection
conservative.
From a public health perspective, our results are consis-
tent with other analyses of vaccine herd protection of
OCVs, both in rural2 and urban–periurban3 cholera-
endemic settings, which demonstrated substantial vaccine
herd protection. Such herd protection greatly enhances the
impact and cost-effectiveness of these vaccines.4 As well,
our results suggest that if small clusters of a population are
vaccinated with OCV in densely populated, urban,
cholera-affected settings, a large proportion of members of
the clusters may fail to be benefitted by herd effects, a
problem that may be addressed by vaccinating large con-
tiguous populations.
Our analyses also have implications for the design and
analysis of future CRTs of vaccines intended to evaluate
population-level vaccine herd protection. CRTs are ac-
knowledged to be the best design for arriving at unbiased
estimates of vaccine herd protective effects.6 However, a
caveat of this assertion is that clusters are selected and de-
fined in such a fashion that they are true epidemiological
units of person-to-person transmission, meaning that no
such transmission of the target pathogen occurs into the
clusters from the surrounding populations. In practice, it
will be uncommon that selected clusters will meet this ide-
alized condition, and measured vaccine herd protective
effects may be diluted to the extent to which the condition
is violated.9 One approach that is commonly used in CRTs
is to create buffer zones between clusters, as was done in
this trial. However, as illustrated by our analysis, buffer
zones, while potentially useful for minimizing diffusion of
interventions between clusters, are not necessarily effective
in preventing transmission of pathogens into clusters from
the outside. Because it may be difficult to predict in ad-
vance whether such transmission will occur in a CRT of
vaccines, some variant of the fried-egg design may be con-
sidered to determine inner cluster sizes for primary analy-
ses of vaccine protection, or at least explored in secondary
sensitivity analyses.
In conclusion, our reanalysis of this trial revealed high
levels of OCV herd protection in innermost populations of
clusters, which had been obscured in analyses of entire
clusters. These data should provide reassurance to policy-
makers regarding the use of OCVs in densely populated,
poor urban settings, where the force of cholera infection
may be high. Our findings also sound a note of caution
that CRTs of vaccines against infections transmitted from
person to person in which clusters fail to fulfill epidemio-
logical assumptions about transmission of the target patho-
gen may underestimate vaccine herd effects.
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